ADRN Barrier/Immunoprofiling Exploratory Pilot Study

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID) (NIH)

Overall Status

Completed

CT.gov ID

NCT02115399

Collaborator

Atopic Dermatitis Research Network (Other)

150

Enrollment

Locations

Duration (Months)

Patients Per Site

3.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to look at how defects in the skin barrier and immune response affect risk for skin infections.

Participants will be classified into 4 groups based on Atopic Dermatitis (AD)/Non-Atopic (NA) status and Staphylococcus aureus (S. aureus) colonization (negative or positive):

AD S. aureus negative
AD S. aureus positive
NA S. aureus negative and
NA S. aureus positive.

Condition or Disease	Intervention/Treatment	Phase
Dermatitis Dermatitis, Atopic Eczema Non-atopic Healthy Controls

Detailed Description

Atopic dermatitis, also called eczema, is a disease in which the skin is dry and scaly with severe itching. People with atopic dermatitis have defects in the skin barrier as well as defects in the immune system which fights off skin infections. People who have atopic dermatitis often have complications from viral and bacterial skin infections, such as recurring Staphylococcus aureus (S. aureus), or Staph infections.

The study will compare the skin barrier and immune response of people with and without atopic dermatitis in relation to whether Staph bacteria is growing on their skin.

Study Design

Study Type:

Observational

Actual Enrollment :

150 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)

Study Start Date :

Apr 1, 2014

Actual Primary Completion Date :

Mar 1, 2015

Actual Study Completion Date :

Jun 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
ADStaph- Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
ADStaph+ Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
NAStaph- Non-atopic healthy participants without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group
NAStaph+ Non-atopic healthy participants with S. aureus skin colonization. As the NAStaph+ phenotype is expected to be rare, as many participants as possible will be enrolled in this group; however, we do not expect to enroll 45 participants in this group.

Outcome Measures

Primary Outcome Measures

The area under the transepidermal water loss (TEWL) curve [6 month]
TEWL will be assessed using the AquaFlux AF200 (Biox, London UK) Transepidermal water loss (TEWL) will be assessed on non-lesional skin prior to tape stripping and repeated after 5, 10, 15, and 20 tape strips

Secondary Outcome Measures

Basal transepidermal water loss (TEWL) [6 month]
TEWL will be assessed using the AquaFlux AF200 (Biox, London UK)
Transepidermal water loss (TEWL) measured after 20 tape strips [6 month]
Transepidermal water loss (TEWL) will be assessed using the AquaFlux AF200 (Biox, London UK). TEWL assessments will be done on non-lesional skin prior to tape stripping and after 20 tape strips and on unstripped lesional skin.
Change in transepidermal water loss (TEWL) [6 month]
Transepidermal water loss (TEWL) will be assessed using the AquaFlux AF200 (Biox, London UK). TEWL after 20 tape strips minus transepidermal water loss (TEWL) prior to tape stripping.
Change in transepidermal water loss (TEWL) per every 5 tape strips (i.e. slope) [6 month]
TEWL will be assessed using the AquaFlux AF200 (Biox, London UK)
Stratum Corneum (SC) hydration (capacitance) [6 month]
Stratum Corneum(SC) hydration will be assessed on lesional and non-lesional skin using the Corneometer® CM825
Surface pH [6 month]
Surface pH will be assessed on lesional and non-lesional skin using the Skin-pH Meter® PH 905
Stratum Corneum (SC) cohesion assessed as total protein removed per D-Squame tape [6 month]
The assessment of SC cohesion will be conducted by two different methods. First, serial measurements of transepidermal water loss (TEWL) will be performed after tape stripping. Second, the amount of protein removed per strip will be calculated by an optical absorbance technique using a CuDerm SquameScan 850A.
Peripheral blood mononuclear cells (PBMC) expression of cell surface and intracellular markers [6 month]
Measured after ex vivo stimulation with a polyclonal T cell stimulus, toll-like receptor ligands (TLRs), iron-regulated surface determinant B (IsdB) as an immunodominant S. aureus antigen, and recall antigens, such as influenza and tetanus antigens, and media alone as the control.
Itch assessment [6 month]
Standardized questionnaires will be used to collect information regarding contact itch intensity
Quality of Life (QoL) measurement [6 month]
Standardized questionnaires will be used to collect information regarding Quality of Life
Transepithelial Electrical Resistance (TEER) assessment from skin biopsies [6 month]
Two punch biopsies of non-lesional skin will be obtained. One biopsy will be used for assessments of Tight Junction (TJ) function including confocal imaging, Transepithelial Electrical Resistance (TEER), and permeability measurements
Permeability assessment from skin biopsies [6 month]
Two punch biopsies of non-lesional skin will be obtained. One biopsy will be used for assessments of Tight Junction (TJ) function including confocal imaging, Transepithelial Electrical Resistance (TEER), and permeability measurements.
Confocal staining of Tight Junction (TJs) from skin biopsies [6 month]
Two punch biopsies of non-lesional skin will be obtained. One biopsy will be used for confocal staining of Tight Junction (TJs) and routine histology.
Atopic Dermatitis (AD) severity assessments [6 month]
AD severity assessments include the Eczema Area and Severity Index (EASI), Rajka-Langeland (R-L) score, and Investigator Global Assessment (IGA)
Analysis of S. aureus isolates for antibiotic sensitivity [6 month]
Antibiotic resistance is characterized by methicillin sensitive Staphylococcus aureus (MSSA) vs. methicillin resistant Staphylococcus aureus (MRSA)
Analysis of S. aureus isolates for expression of virulence or other factors [6 month]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 60 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Participants fulfilling all of the following criteria are eligible for enrollment-

Non-Hispanic Caucasian males and females 18 to 60 years of age, inclusive, at the time of Enrollment
Who are enrolled in the ADRN Registry study
Who have active AD (lesions present) with or without a history of Eczema Herpeticum (EH) as defined in the ADRN Standard Diagnostic Criteria OR who meet criteria for the NA diagnostic group as defined in the ADRN Standard Diagnostic Criteria
Who are willing to sign the informed consent form prior to initiation of any study procedures.

Exclusion Criteria:

Participants fulfilling any of the following criteria are not eligible for enrollment-

Who are pregnant
Who have an active systemic malignancy. Uncomplicated non-melanoma skin cancer and melanoma in situ with documentation of complete excision are not exclusionary
Who have any skin disease other than AD that might compromise the SC barrier (e.g., bullous disease, psoriasis, cutaneous T cell lymphoma [also called Mycosis Fungoides or Sezary syndrome], dermatitis herpetiformis, Hailey-Hailey, or Darier's disease)
Who have a history of systemic immunological illness (e.g., human immunodeficiency virus [HIV] or systemic lupus erythematosus [SLE]) other than the condition being studied
Who have active EH or eczema vaccinatum (EV)
Who have a history of serious or life-threatening reaction to latex, tape, or adhesives
Who are determined to be not eligible based on the opinion of the Investigator.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	National Jewish Health	Denver	Colorado	United States	80206
2	University of Rochester	Rochester	New York	United States	14642
3	Oregon Health & Science University	Portland	Oregon	United States	97239